MYK-224 HFpEF AURORA Phase II — PatSnap Eureka
MYK-224 in HFpEF: BMS's AURORA Phase II and the Cardiac Myosin Inhibitor Frontier
MYK-224 is Bristol Myers Squibb's investigational small-molecule cardiac myosin inhibitor entering Phase II evaluation in heart failure with preserved ejection fraction — a condition affecting ~50% of all heart failure patients with historically limited disease-modifying options. Explore the science, competitive landscape, and patent intelligence powering this programme.
How MYK-224 Targets the Root Cause of Diastolic Dysfunction
MYK-224 is a selective small-molecule inhibitor of cardiac myosin ATPase, the molecular motor responsible for driving cardiomyocyte contraction. In heart failure with preserved ejection fraction (HFpEF), the fundamental problem is not weak contraction — systolic function remains intact — but rather impaired ventricular relaxation and elevated filling pressures during diastole.
By reducing the proportion of myosin heads in the force-generating state, MYK-224 aims to decrease myofilament activation, lower energy consumption per beat, and restore normal cross-bridge cycling kinetics. This approach targets the mechanistic underpinning of diastolic stiffness, rather than addressing downstream haemodynamic consequences.
This mechanism is distinct from mavacamten's indication in obstructive HCM, where the primary therapeutic goal is reducing left ventricular outflow tract (LVOT) obstruction. In HFpEF, there is no obstruction — the target is the myocardial relaxation impairment itself, which makes MYK-224 a mechanistically novel approach to this unmet need.
The patent landscape around cardiac myosin inhibition has expanded significantly since the validation of mavacamten, with BMS filing a series of structural analogues and formulation patents covering next-generation compounds including MYK-224.
HFpEF: The Largest Unaddressed Heart Failure Population
Heart failure with preserved ejection fraction affects approximately half of all heart failure patients globally, yet has historically lacked the disease-modifying therapies available for reduced ejection fraction heart failure.
~50% of Heart Failure Cases Are HFpEF
HFpEF accounts for approximately half of all heart failure diagnoses. The condition is characterised by symptoms of breathlessness and exercise intolerance in the setting of a preserved left ventricular ejection fraction (≥50%), elevated filling pressures, and diastolic dysfunction. Prevalence is rising as the population ages and obesity rates increase — both major risk factors for HFpEF.
LVEF ≥50% defining criterionLimited Disease-Modifying Therapies Until Recently
Unlike heart failure with reduced ejection fraction (HFrEF), where ACE inhibitors, beta-blockers, MRAs, and sacubitril/valsartan have demonstrated clear mortality benefit, HFpEF lacked equivalent therapies for decades. SGLT2 inhibitors empagliflozin and dapagliflozin have more recently demonstrated outcome benefits in HFpEF, but the mechanistic gap for myofilament-directed therapy remains open.
SGLT2i: current standard of careDiastolic Dysfunction and Elevated Filling Pressures
The central haemodynamic abnormality in HFpEF is impaired left ventricular relaxation (diastolic dysfunction) leading to elevated left ventricular end-diastolic pressure and pulmonary venous congestion. Left ventricular hypertrophy, myocardial fibrosis, and cardiomyocyte stiffness all contribute. MYK-224's myosin-inhibiting mechanism directly targets the cross-bridge cycling abnormalities that drive this stiffness.
LV hypertrophy & fibrosis co-driversObesity, Hypertension, and Metabolic Syndrome as Key Drivers
HFpEF is strongly associated with obesity, hypertension, diabetes, and atrial fibrillation. This systemic inflammatory and metabolic context complicates trial design and patient selection. The AURORA trial for MYK-224 must navigate this heterogeneous patient population, and biomarker-based patient stratification — including natriuretic peptides and echocardiographic diastolic indices — will be critical to demonstrating efficacy signals.
Metabolic phenotype dominant in HFpEFCardiac Myosin Inhibitor Landscape at a Glance
Key data visualisations derived from patent and clinical literature analysis, illustrating the development stage distribution and HFpEF disease burden context for MYK-224.
HFpEF vs. HFrEF: Share of All Heart Failure Cases
HFpEF accounts for approximately 50% of all heart failure diagnoses globally, representing a population of tens of millions with historically limited disease-modifying options.
Cardiac Myosin Modulator Development Stage Comparison
MYK-224 is the only cardiac myosin inhibitor in Phase II evaluation specifically for HFpEF, positioning BMS uniquely in this mechanistic space.
MYK-224 vs. the Broader HFpEF Therapeutic Landscape
MYK-224 enters a competitive HFpEF space that includes approved SGLT2 inhibitors, investigational agents, and the validated cardiac myosin inhibitor class from which it derives.
Track Every HFpEF Programme in Real Time
PatSnap Eureka monitors patent filings, clinical updates, and regulatory milestones across the full HFpEF pipeline.
Why MYK-224 and AURORA Matter for R&D and IP Teams
Key strategic considerations for pharmaceutical R&D, IP, and business development professionals tracking the cardiac myosin inhibitor class and HFpEF drug discovery.
BMS's Platform Leverage from Mavacamten to MYK-224
BMS acquired the cardiac myosin inhibitor platform through its 2021 acquisition of MyoKardia for $13.1 billion. MYK-224 represents the strategic extension of that investment into HFpEF — a far larger patient population than HCM. The AURORA trial is BMS's attempt to demonstrate that the validated myosin inhibitor mechanism can be repositioned for the broader heart failure market.
HFpEF Trial Design Challenges: Patient Heterogeneity
HFpEF is notoriously heterogeneous — patients range from obese metabolic phenotypes to hypertensive LV hypertrophy phenotypes. This heterogeneity has contributed to numerous failed HFpEF trials. AURORA's success will depend on rigorous patient selection criteria, likely using echocardiographic diastolic parameters, natriuretic peptide levels, and potentially cardiac imaging biomarkers to enrich for responders to myosin inhibition.
AI-Powered Intelligence for Cardiac Myosin Inhibitor Research
PatSnap Eureka provides R&D teams, IP professionals, and business development strategists with AI-native intelligence across patents, clinical literature, and regulatory filings — enabling faster, more confident decisions in competitive drug discovery environments like cardiac myosin inhibition.
For MYK-224 and the HFpEF therapeutic landscape, Eureka enables teams to track BMS's evolving patent portfolio across cardiac myosin inhibitor structural analogues, monitor competitor filings from Cytokinetics and other life sciences innovators, and identify white-space opportunities in diastolic dysfunction drug discovery.
The platform integrates data from over 2 billion data points across 120+ countries, enabling global patent landscape analysis that captures the full competitive picture — from early-stage academic filings to late-stage regulatory submissions. Teams using PatSnap Eureka report up to 75% faster research timelines and 25% reduction in duplicated R&D effort.
For enterprise IP and compliance requirements, PatSnap's trust and security framework ensures that sensitive R&D intelligence workflows meet the highest data protection standards — critical for pharmaceutical organisations tracking competitive intelligence in active clinical programmes like AURORA.
MYK-224 HFpEF AURORA Phase II — key questions answered
MYK-224 is a small-molecule cardiac myosin inhibitor developed by Bristol Myers Squibb (BMS). It works by reducing the ATPase activity of cardiac myosin, thereby decreasing excessive myofilament activation. In HFpEF, where diastolic dysfunction and impaired ventricular relaxation are key pathological drivers, MYK-224 aims to restore normal cross-bridge cycling kinetics and improve left ventricular compliance.
AURORA is a Phase II clinical trial evaluating MYK-224 in patients with heart failure with preserved ejection fraction (HFpEF). The trial is designed to assess the safety, tolerability, and efficacy signals of MYK-224 in this difficult-to-treat patient population, where left ventricular ejection fraction is typically ≥50% but diastolic function is impaired.
Mavacamten (Camzyos) is a cardiac myosin inhibitor approved for obstructive hypertrophic cardiomyopathy (HCM), targeting a different patient population to MYK-224. While both compounds inhibit cardiac myosin ATPase activity, MYK-224 is being specifically developed and evaluated for HFpEF, a broader and distinct heart failure syndrome characterised by preserved ejection fraction rather than outflow tract obstruction.
HFpEF accounts for approximately 50% of all heart failure cases and has historically lacked disease-modifying therapies. The condition is characterised by preserved left ventricular ejection fraction (≥50%), diastolic dysfunction, elevated filling pressures, and symptoms of breathlessness and exercise intolerance. Despite its high prevalence and mortality burden, therapeutic options remain limited, making novel mechanisms like cardiac myosin inhibition highly relevant.
The cardiac myosin inhibitor class is led by mavacamten (BMS/MyoKardia, approved for HCM) and aficamten (Cytokinetics, in late-stage HCM trials). MYK-224 represents BMS's strategic extension of this mechanism into HFpEF. Omecamtiv mecarbil, a myosin activator with the opposite mechanism, has been evaluated in HFrEF. The HFpEF space also sees competition from SGLT2 inhibitors (empagliflozin, dapagliflozin) which have demonstrated outcome benefits in this population.
PatSnap Eureka provides AI-powered patent and literature intelligence that allows researchers, IP teams, and R&D strategists to monitor MYK-224's patent filings, track BMS's broader cardiac myosin inhibitor portfolio, map the competitive landscape across HFpEF therapeutics, and identify white-space opportunities in diastolic dysfunction drug discovery.
Still have questions about MYK-224 or HFpEF drug development? Let PatSnap Eureka answer them.
Ask PatSnap Eureka →Accelerate Your HFpEF and Cardiac Myosin Inhibitor Research
Join 18,000+ innovators already using PatSnap Eureka to map drug pipelines, analyse patent landscapes, and discover competitive intelligence across cardiology and beyond.
References
- National Institutes of Health (NIH) — Heart Failure Research and Clinical Resources
- ClinicalTrials.gov — MYK-224 AURORA Phase II Trial Registry
- European Society of Cardiology (ESC) — HFpEF Guidelines and Clinical Guidance
- U.S. Food and Drug Administration (FDA) — Mavacamten (Camzyos) Approval and Cardiac Myosin Inhibitor Regulatory Framework
- American Heart Association Journals — EMPEROR-Preserved and DELIVER Trial Publications on SGLT2 Inhibitors in HFpEF
- New England Journal of Medicine — Cardiac Myosin Inhibitor Clinical Trial Results and HFpEF Mechanistic Studies
- PatSnap — IP Analytics and Patent Landscape Analysis Platform
- PatSnap — Life Sciences Innovation Intelligence Solutions
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Clinical development stage information reflects publicly available data at time of publication and may change as programmes advance.
PatSnap Eureka searches patents and research to answer instantly.